BIOMAT Database Logo BIOMAT Database Logo

Orally active beta-lactam inhibitors of human leukocyte elastase. 2. Effect of C-4 substitution. 1993

W K Hagmann, and A L Kissinger, and S K Shah, and P E Finke, and C P Dorn, and K A Brause, and B M Ashe, and H Weston, and A L Maycock, and W B Knight
Department of Medicinal Chemical Research, Merck Research Laboratories, Rahway, New Jersey 07065.

The effect of changing the C-4 substituent of 3,3-diethyl-1-[(benzylamino)carbonyl]-2-azetidinone on inhibition of HLE and in a model of HLE-induced lung damage in hamsters was explored. Substituents at this position do not appear to interact strongly with HLE with the most potent compounds having k(obs)/[I] = 6900 M-1 s-1. However, substituents at this position had a marked effect on in vivo activity. The greatest oral activity in the lung hemorrhage assay was achieved with C-4 aryl carboxylic acid ethers (60-85% inhibition at 30 mg/kg po). Based upon the established mechanism of inhibition by these compounds, the C-4 substituent would be released, and therefore, the pharmacological potential of these C-4 substituents was of considerable concern. Fortunately, compounds containing 4-hydroxybenzoic acid and 4-hydroxyphenylacetic acid ethers at C-4 were among the most active analogs. These phenolic acids are also found as urinary metabolites in healthy humans. Other heteroaryls at C-4 were also orally active in this model despite relatively modest enzyme activity.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008997 Monobactams Monocyclic, bacterially produced or semisynthetic beta-lactam antibiotics. They lack the double ring construction of the traditional beta-lactam antibiotics and can be easily synthesized. Antibiotics, Monobactam,Monobactam,Monocyclic beta-Lactam,Monocyclic beta-Lactams,beta-Lactams, Monocyclic,Monobactam Antibiotics,Monocyclic beta Lactam,Monocyclic beta Lactams,beta Lactams, Monocyclic,beta-Lactam, Monocyclic
D010196 Pancreatic Elastase A protease of broad specificity, obtained from dried pancreas. Molecular weight is approximately 25,000. The enzyme breaks down elastin, the specific protein of elastic fibers, and digests other proteins such as fibrin, hemoglobin, and albumin. EC 3.4.21.36. Elastase,Pancreatopeptidase,Elastase I,Pancreatic Elastase I,Elastase I, Pancreatic,Elastase, Pancreatic
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006470 Hemorrhage Bleeding or escape of blood from a vessel. Bleeding,Hemorrhages
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D019272 Leukocyte Elastase An enzyme that catalyzes the hydrolysis of proteins, including elastin. It cleaves preferentially bonds at the carboxyl side of Ala and Val, with greater specificity for Ala. EC 3.4.21.37. Lysosomal Elastase,Neutrophil Elastase,PMN Elastase,Polymorphonuclear Leukocyte Elastase,Granulocyte Elastase,Elastase, Granulocyte,Elastase, Leukocyte,Elastase, Lysosomal,Elastase, Neutrophil,Elastase, PMN,Elastase, Polymorphonuclear Leukocyte,Leukocyte Elastase, Polymorphonuclear

Related Publications

W K Hagmann, and A L Kissinger, and S K Shah, and P E Finke, and C P Dorn, and K A Brause, and B M Ashe, and H Weston, and A L Maycock, and W B Knight
Orally active beta-lactam inhibitors of human leukocyte elastase. 3. Stereospecific synthesis and structure-activity relationships for 3,3-dialkylazetidin-2-ones.
June 1995, Journal of medicinal chemistry,
W K Hagmann, and A L Kissinger, and S K Shah, and P E Finke, and C P Dorn, and K A Brause, and B M Ashe, and H Weston, and A L Maycock, and W B Knight
Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.
September 1997, Journal of medicinal chemistry,
W K Hagmann, and A L Kissinger, and S K Shah, and P E Finke, and C P Dorn, and K A Brause, and B M Ashe, and H Weston, and A L Maycock, and W B Knight
Design of orally active, non-peptidic inhibitors of human leukocyte elastase.
April 1994, Journal of medicinal chemistry,
W K Hagmann, and A L Kissinger, and S K Shah, and P E Finke, and C P Dorn, and K A Brause, and B M Ashe, and H Weston, and A L Maycock, and W B Knight
Orally bioavailable benzisothiazolone inhibitors of human leukocyte elastase.
March 1995, Journal of medicinal chemistry,
W K Hagmann, and A L Kissinger, and S K Shah, and P E Finke, and C P Dorn, and K A Brause, and B M Ashe, and H Weston, and A L Maycock, and W B Knight
2-(diethylamino)thieno1,3Ċxazin-4-ones as stable inhibitors of human leukocyte elastase.
December 1999, Journal of medicinal chemistry,
W K Hagmann, and A L Kissinger, and S K Shah, and P E Finke, and C P Dorn, and K A Brause, and B M Ashe, and H Weston, and A L Maycock, and W B Knight
Development of orally active nonpeptidic inhibitors of human neutrophil elastase.
April 2001, Journal of medicinal chemistry,
W K Hagmann, and A L Kissinger, and S K Shah, and P E Finke, and C P Dorn, and K A Brause, and B M Ashe, and H Weston, and A L Maycock, and W B Knight
Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys.
August 1997, Drug metabolism and disposition: the biological fate of chemicals,
W K Hagmann, and A L Kissinger, and S K Shah, and P E Finke, and C P Dorn, and K A Brause, and B M Ashe, and H Weston, and A L Maycock, and W B Knight
Orally active inhibitors of human leukocyte elastase. I. Disposition of L-683,845 in rats and rhesus monkeys.
December 1996, Drug metabolism and disposition: the biological fate of chemicals,
W K Hagmann, and A L Kissinger, and S K Shah, and P E Finke, and C P Dorn, and K A Brause, and B M Ashe, and H Weston, and A L Maycock, and W B Knight
Inhibitors of human leukocyte elastase.
January 1994, Progress in medicinal chemistry,
W K Hagmann, and A L Kissinger, and S K Shah, and P E Finke, and C P Dorn, and K A Brause, and B M Ashe, and H Weston, and A L Maycock, and W B Knight
Pharmacological evaluation of selected, orally active, peptidyl inhibitors of human neutrophil elastase.
December 1995, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!